MYMX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Feb 2024 @ 12:47):

Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland...

Stats
Today's Volume	23.00
Average Volume	12.00
Market Cap	3.04M
EPS	€-0.00367 ( 2023-11-20 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	0
ATR14	€0.126 (1 260.00%)

Insider Trading

Date	Person	Action	Amount	type
2015-04-09	Kempers Ronald Hugo Gerard	Buy	5 000 000	Stock options
2006-01-31	Round Enterprises, Ltd.	Sell	0	Common Stock
2006-01-31	Round Enterprises, Ltd.	Sell	0	Convertible Notes
2013-10-04	Fleury Sylvain	Buy	800 000	Stock Options
2009-12-31	Fleury Sylvain	Buy	350 000	Stock Options

INSIDER POWER
0.00
Last 30 transactions
Buy: 27 300 000 \| Sell: 9 617 276

Volume Correlation

Long: 0.08 (neutral)

Short: 0.00 (neutral)

Signal:(26.769) Neutral

Mymetics Corporation Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mymetics Corporation Correlation - Currency/Commodity

0.60
( weak )

-0.33
( neutral )

-0.03
( neutral )

-0.42
( neutral )

-0.62
( weak negative )

Mymetics Corporation Financials

Annual	2022
Revenue:	€3 000.00
Gross Profit:	€-1.44M (-47 966.67 %)
EPS:	€-0.0259

Q3	2023
Revenue:	€36 986.00
Gross Profit:	€-344 014 (-930.12 %)
EPS:	€-0.00370

Q2	2023
Revenue:	€201 343
Gross Profit:	€6 343.00 (3.15 %)
EPS:	€-0.0253

Q1	2023
Revenue:	€3 000.00
Gross Profit:	€-596 000 (-19 866.67 %)
EPS:	€-0.00310

Financial Reports:

No articles found.

Mymetics Corporation

Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.